The Patent Finder

Terms ending in 2038

Oncotherapy Science, Inc.

Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,079,386Monoclonal Antibody Against FZD10 and Use Thereof
In force
 · High confidence
Oncotherapy Science, Inc.In forceHigh confidence
US 11,066,477Monoclonal Antibody Against Melk and Utilization Thereof
In force
 · High confidence
Oncotherapy Science, Inc.In forceHigh confidence
US 11,091,517Peptide Derivative and Pharmaceutical Composition Containing Same
In force
 · High confidence
Tokushima UniversityIn forceHigh confidence
US 11,242,365FOXM1-DERIVED Peptide, and Vaccine Including Same
In force
 · High confidence
Oncotherapy Science, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Oncotherapy Science, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited